Cervomed Inc (CRVO) Stock Price, Quote & News

Company Profile

CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurologic...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 744 4400

Website: www.cervomed.com

Address:

20 Park Plaza, Suite 424, Boston, United States

Pharoh42 Dec. 2 at 9:40 PM

$CRVO It is like if it will go up someone will die Well, seems like I will take my loss and claim taxes then buy again in a month , it won’t go anywhere

0 · Reply

Stu_padasso Dec. 2 at 9:01 PM

$CRVO wow complete fucking garbage buy back after dilution is my plan

0 · Reply

Doki0926 Dec. 2 at 8:55 PM

$CRVO can someone explain this?

1 · Reply

Messerschmittbf109 Dec. 2 at 7:35 PM

$CRVO they will adjust the dose next step …

0 · Reply

LilyBurger Dec. 2 at 5:46 PM

$CRVO This is great. I just got fisted by my mistress, now I am getting my scrotum slapped raw by CRVO. How lucky can I get. WTF!!

1 · Reply

BPler Dec. 2 at 5:41 PM

$CRVO Every time on good news we see a drop ... is there a rogue algo instant shorting this one every news? The fuckery here is insane ...

1 · Reply

Messerschmittbf109 Dec. 2 at 5:25 PM

$CRVO if true good news

1 · Reply

Stu_padasso Dec. 2 at 5:21 PM

$CRVO 10 million shares at 8 in coming good luck

1 · Reply

Messerschmittbf109 Dec. 2 at 5:15 PM

$CRVO in two days -21% with only 100 k in total they are speculating The actual price is Under the . the last insider purchases

1 · Reply

Disinformation_Consumer Dec. 2 at 4:08 PM

$CRVO It’s a sector wide problem. Other biotechs are down by similar amounts, including profitable ones with higher volume and no dilution fears. Probably related to whater bullshit RFK Jr is doing tomorrow. Still CRVO will probably struggle to reclaim $9 because of the low volume.

1 · Reply

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

Nov 24, 2025, 7:00 AM EST - 8 days ago

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Oct 20, 2025, 8:00 AM EDT - 6 weeks ago

CervoMed to Present at the Emerging Growth Conference

Oct 8, 2025, 11:54 AM EDT - 7 weeks ago

CervoMed Drug Cut Dementia Progression Risk By 75% In Trial

Oct 8, 2025, 7:00 AM EDT - 7 weeks ago

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

Oct 2, 2025, 8:00 AM EDT - 2 months ago

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Sep 17, 2025, 7:30 AM EDT - 2 months ago

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

Sep 3, 2025, 8:00 AM EDT - 3 months ago

CervoMed to Participate in Upcoming Investor Conferences

Jul 28, 2025, 11:20 AM EDT - 4 months ago

CervoMed's Dementia Data Show Slowed Disease Progression

Jul 28, 2025, 7:00 AM EDT - 4 months ago

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

Jul 8, 2025, 7:00 AM EDT - 5 months ago

CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025

May 12, 2025, 8:00 AM EDT - 7 months ago

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Mar 31, 2025, 2:34 PM EDT - 8 months ago

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

CMRX CVS GERN LLY NVO SEPN

Mar 25, 2025, 8:00 AM EDT - 9 months ago

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

Mar 22, 2025, 2:55 AM EDT - 9 months ago

CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats

Mar 10, 2025, 4:05 PM EDT - 9 months ago

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

Jan 29, 2025, 8:00 AM EST - 10 months ago

CervoMed to Present at the 8th International Lewy Body Dementia Conference

Dec 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 10, 2024, 11:37 AM EST - 1 year ago

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets

Dec 10, 2024, 10:10 AM EST - 1 year ago

CervoMed's stock craters 77% after failed trial of treatment for rare brain disease

Dec 10, 2024, 7:33 AM EST - 1 year ago

CervoMed's dementia drug fails to meet mid-stage trial goals

Dec 10, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

Nov 27, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Nov 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 8, 2024, 9:55 AM EST - 1 year ago

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

Nov 4, 2024, 8:00 AM EST - 1 year ago

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

Oct 29, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Oct 2, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

Aug 22, 2024, 8:00 AM EDT - 1 year ago

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

Jul 30, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

Jul 17, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in the Emerging Growth Conference

Jul 11, 2024, 8:51 AM EDT - 1 year ago

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

Jun 11, 2024, 8:00 AM EDT - 1 year ago

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

May 20, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Appoint William Elder as Chief Financial Officer

May 15, 2024, 8:00 AM EDT - 1 year ago

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Apr 2, 2024, 2:59 AM EDT - 1 year ago

CervoMed: H2 2024 Data For DLB Program A Major Inflection Point

Apr 1, 2024, 8:00 AM EDT - 1 year ago

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Mar 28, 2024, 8:30 AM EDT - 1 year ago

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

Mar 5, 2024, 8:00 AM EST - 1 year ago

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Feb 21, 2024, 8:00 AM EST - 1 year ago

CervoMed to Participate in the BIO CEO and Investor Conference

Feb 12, 2024, 8:00 AM EST - 1 year ago

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

Feb 7, 2024, 8:30 AM EST - 1 year ago

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

Feb 5, 2024, 8:00 AM EST - 1 year ago

CervoMed to Participate in the Emerging Growth Conference 67

Jan 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 66

Nov 13, 2023, 7:00 AM EST - 2 years ago

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 25, 2023, 2:50 PM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies

Oct 24, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias

Oct 18, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies

Oct 5, 2023, 7:00 AM EDT - 2 years ago

CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference

Sep 5, 2023, 7:00 AM EDT - 2 years ago

CervoMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

Pharoh42 Dec. 2 at 9:40 PM

$CRVO It is like if it will go up someone will die Well, seems like I will take my loss and claim taxes then buy again in a month , it won’t go anywhere

0 · Reply

Stu_padasso Dec. 2 at 9:01 PM

$CRVO wow complete fucking garbage buy back after dilution is my plan

0 · Reply

Doki0926 Dec. 2 at 8:55 PM

$CRVO can someone explain this?

1 · Reply

Messerschmittbf109 Dec. 2 at 7:35 PM

$CRVO they will adjust the dose next step …

0 · Reply

LilyBurger Dec. 2 at 5:46 PM

$CRVO This is great. I just got fisted by my mistress, now I am getting my scrotum slapped raw by CRVO. How lucky can I get. WTF!!

1 · Reply

BPler Dec. 2 at 5:41 PM

$CRVO Every time on good news we see a drop ... is there a rogue algo instant shorting this one every news? The fuckery here is insane ...

1 · Reply

Messerschmittbf109 Dec. 2 at 5:25 PM

$CRVO if true good news

1 · Reply

Stu_padasso Dec. 2 at 5:21 PM

$CRVO 10 million shares at 8 in coming good luck

1 · Reply

Messerschmittbf109 Dec. 2 at 5:15 PM

$CRVO in two days -21% with only 100 k in total they are speculating The actual price is Under the . the last insider purchases

1 · Reply

Disinformation_Consumer Dec. 2 at 4:08 PM

1 · Reply

Stu_padasso Dec. 2 at 3:29 PM

$CRVO something isnt right here good luck take my small loss and move on be sure to troll me when it goes to 30 lol

1 · Reply

Messerschmittbf109 Dec. 2 at 3:28 PM

$CRVO capitulating with 30 k Boooo fear 🤡🤡🤡🤡 Clowns all in general

1 · Reply

Scorpole Dec. 2 at 3:27 PM

$CRVO Indiders buy looks like to be an attempt to higher the price for the next offering

1 · Reply

Messerschmittbf109 Dec. 2 at 3:24 PM

$CRVO analysts says 31 and this doesn’t gotcha 9??? 🤡🤡🤡🤡🤡

0 · Reply

Stu_padasso Dec. 2 at 3:20 PM

$CRVO what utter garbage they will fucking dilute soon

0 · Reply

Doki0926 Dec. 2 at 2:51 PM

$CRVO 😂😂😂😂😂😂😂😂😂😂😂😂😂😂😂😂😂😂😂😂😂😂😂😂😂

1 · Reply

Messerschmittbf109 Dec. 2 at 2:31 PM

$CRVO 16-18

1 · Reply

5layer Dec. 2 at 2:24 PM

$CRVO wtf?

0 · Reply

pitkineagle Dec. 2 at 1:54 PM

$CRVO Alam should try for accelerated approval from the FDA for Neflamapimod. Clearly would improve multiple lives now instead of waiting two years for Phase 3 and subsequent approval.

0 · Reply

JarvisFlow Dec. 2 at 1:46 PM

D. Boral Capital has updated their rating for CervoMed ( $CRVO ) to Buy with a price target of 31.

0 · Reply

1K21Mil Dec. 2 at 1:32 PM

$CRVO CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB) https://finance.yahoo.com/news/cervomed-presents-plasma-biomarker-data-120000410.html

0 · Reply

Doom_Gloom_AR Dec. 2 at 1:15 PM

$CRVO biomarkers on par with Lecanemab, this might get us over the breakthrough designation hump.

1 · Reply

Market Cap	85.31M
Revenue (ttm)	9.74M
Net Income (ttm)	-16.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-167.25%
Debt to Equity Ratio	0.00

Volume	136,600
Avg Vol	91,322
Day's Range	N/A - N/A
Shares Out	9.25M
Stochastic %K	10%
Beta	-0.91
Analysts	Strong Sell
Price Target	$22.43